While HCPs are turning away from in-person meetings with sales reps amidst the COVID-19 pandemic, there are still strategies for them to keep their pipelines full.
By integrating support directly into existing workflows and focusing on solutions that eliminate "shoulder time," manufacturers can significantly reduce delays and improve patient outcomes.
Shifting from the volume of data to the value of insights
Additional assistance necessary for patients prescribed specialty therapies.
Identifying unique traits in patients is key to creating the most effective support programs.
Thursday June 8, 2022 at 11am PDT | 2pm EDT | 7pm BST | 8pm CEST Learn how life sciences companies can navigate growth by leveraging NetSuite for streamlined processes, better management reporting, and stronger financial controls to ensure real-time management decision-making and regulatory compliance.
This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.
Ahmed Bouzidi explores the opportunities and challenges facing small and mid-size biopharma companies as they strive to bring their latest innovations to market.
Strategies to become a Certified B Corporation, and the benefits to the industry, its stakeholders, and the world.
Faster launch planning leads to greater access.
A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.
Janita Good looks at some of the therapeutics currently under investigation and the issues they have highlighted in the context of a pandemic.
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Pharma marketing strategies that are both socially and ethically responsible can build long term success for the life sciences industry.
Value-based price for access (VBPA) may increase access of specialty drugs for patients.
A new patient journey is emerging. Gilda Sala, Trista Bridges, and Rune Soelvsteen offer easy steps to future-proof your company’s approach.
Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
Defining what Gross-to-Net mean and why it is important to Life Sciences companies; Identify who in the company benefits in utilizing information from GTN; Get insights to successfully define and manage GTN process
Here are three mindsets for pharma companies to adopt now to reap the rewards of early action in the metaverse.
Unlock the secrets of executive presence in pharma to inspire confidence, influence decisions, and elevate your leadership impact.
If used properly, AI can be a game-changer for drug development.
Why pharma needs to focus on improving—not just extending life.
Biopharma marketers use experience to grow brands into fixtures in patient discourse
Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or metastatic cancer.
Hannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.
This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.
While hurdles remain, home healthcare could deliver better patient-centered cancer care—providing improved outcomes, enhanced quality of life, and reduced strain on resources.